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The incorporation of unsaturated acyl 
chains into phospholipids during de novo 
synthesis is primarily mediated by the 1-acyl-
sn-glycerol-3-phosphate acyltransferase 
reaction.  In S. cerevisiae, Slc1 has been shown 
to mediate this reaction but distinct activity 
remains after its removal from the genome.  To 
identify the enzyme that mediates the 
remaining activity, we performed synthetic 
genetic array analysis using a slc1Δ strain.  One 
of the genes identified by the screen, LPT1, was 
found to encode for an acyltransferase that uses 
a variety of lysophospholipid species, including 
1-acyl-sn-glycerol-3-phosphate.  Deletion of 
LPT1 had a minimal effect on 1-acyl-sn-
glycerol-3-phosphate acyltransferase activity 
but over-expression increased activity 7-fold.   
Deletion of LPT1 abrogated the esterification of 
other lysophospholipids and over-expression 
increased lysophosphatidylcholine 
acyltransferase activity 7-fold.  The majority of 
this activity co-purified with microsomes.  To 
test the putative role for this enzyme in 
selectively incorporating unsaturated acyl 
chains into phospholipids, in vitro, substrate 
concentration series experiments were 
performed with the four acyl-CoA species 
commonly found in yeast.  While the saturated 
palmitoyl-CoA and stearoyl-CoA showed a 
lower apparent Km, the monounsaturated 
palmitoleoyl-CoA and oleoyl-CoA showed a 
higher apparent Vmax.  Arachidonyl-CoA, 
although not abundant in yeast, also had a high 
apparent Vmax.  Pulse-labeling of lpt1Δ strains 
showed a 30% reduction in [3H]oleate 
incorporation into phosphatidylcholine only.  
Therefore, Lpt1p, a member of the membrane 
bound o-acyltransferase gene family, seems to 
work in conjunction with Slc1 to mediate the 
incorporation of unsaturated acyl-chains into 
the sn-2 position of phospholipids. 
It has long been known that phospholipids 
commonly contain an asymmetrical distribution of 
acyl chains (1,2).  Saturated acyl chains are 
usually found at the sn-1 position and unsaturated 
acyl chains at sn-2.  The reason for this asymmetry 
may be that the liquid crystal transition 
temperature (Tc) for phospholipids with two 
saturated acyl chains, such as distearoyl 
phosphatidylcholine (58° C), is much higher than 
that for 1-stearoyl-2-oleoyl phosphatidylcholine 
(3° C) (3).  The incorporation of unsaturated acyl 
chains prevents membranes from assuming the gel 
phase at common physiological temperatures. 
During the de novo synthesis of phospholipids 
(Fig. 1a), acyl chains are incorporated into the sn-2 
position by 1-acyl-sn-glycerol-3-phosphate 
acyltransferase (AGPAT)4, also known as 
lysophosphatidic acid acyltransferase (LPAAT).  
The acyl-CoA substrate specificity for the reaction 
in rat liver microsomes (4) and by over-expressed 
human AGPAT1 (5,6) and AGPAT2 (6,7) show 
only a mild, if any, preference for unsaturated 
species.  Thus, while the reaction produces a 
necessary intermediate, phosphatidic acid, in the 
synthesis of phospholipids and triglycerides, the 
substrate specificity does not match the acyl chain 
composition of most phospholipids.  However, the 
reaction clearly has physiological importance 
since mutations in AGPAT2 result in the dramatic 
lack of many, but not all, adipose depots in 
congenital general lipodystrophy (8).  Given this 
necessity of AGPAT2 function, it is surprising that 
there are nine AGPAT paralogs in humans.  
AGPAT6 has been implicated in triglyceride 
synthesis in mammary glands (9).  AGPAT8 
encodes for an endoplasmic reticulum glycerol 3-
phosphate acyltransferase (10) and AGPAT9 is 
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highly homologous to lysophosphatidylcholine 
acyltransferase 1 (LPCAT1) (11).  Whether the 
members of this gene family are responsible for all 
AGPAT activity in mammals cannot be practically 
determined.  The only AGPAT gene family 
member in the S. cerevisiae is SLC1.  SLC1 
deletion mutants contain no AGPAT activity in 
lipid particles and about 50% activity in 
microsomes (12).  Clearly, a unique AGPAT 
exists in the yeast genome. 
AGPAT's product, phosphatidic acid, can be 
used to synthesize phospholipids by two pathways 
(Fig. 1a) (reviewed in (13)).  Additionally, after de 
novo synthesis, phospholipids can undergo 
remodeling (Fig. 1b).  This involves deacylation at 
the sn-2 position by phospholipase A2 and 
reacylation by acyl-CoA-dependent 
lysophospholipid acyltransferase (Lands' Cycle) 
(14).  There are many possible physiological 
functions of this remodeling which may be 
organism and cell type specific.  In addition to 
incorporating unsaturated acyl chains for 
membrane fluidity, specific incorporation of the 
polyunsaturated arachidonyl into the sn-2 position 
may prime phospholipase A2 inducible signal 
cascades that involve eicosanoid synthesis (15).  
Alternatively, preferential incorporation of 
saturated acyl chains occurs during surfactant 
production in lungs (16).  The remodeling 
enzymes may also re-esterify exogenous 
lysophospholipids generated by extracellular 
lipases.  For instance, yeast can absorb and esterify 
lysophosphatidylethanolamine (lysoPE) (17).  In 
mammals, this process may prevent the 
inflammation that lysophospholipids can induce 
(18).  To date, the only cloned lysophospholipid 
acyltransferases are the mouse LPCAT1 and lyso-
platelet activating factor acyltransferase 
(lysoPAFAT) / LPCAT2 (19-21).  These are 
primarily expressed in lungs, have a mild 
preference for saturated acyl-CoA, are specific for 
lysophosphatidylcholine (lysoPC) and have 
conserved motifs in common with the AGPAT 
gene family.  In yeast, acyl-CoA-independent 
LPCAT (i.e. transacylase) activity is mediated by 
Taffazin (22) and acyl-CoA dependent LPCAT 
activity has been reported (2,23) but the enzyme 
had not been identified. 
In this study, the application of synthetic 
genetic array (SGA) analysis lead to the 
identification of the enzyme, Lpt1p.  SGA is an 
automated approach to create double gene deletion 
mutants by crossing a gene deletion strain of 
interest and the ~5,000 viable yeast gene deletion 
strains.  Inviability of the double deletion mutants 
(i.e. synthetic lethality) defines a relationship 
whereby mutation in two different genes, neither 
by itself lethal, causes cell death when combined 
in a haploid genome (24).  Such genetic 
interactions are of particular interest because they 
can identify genes whose products perform 
complementary biological functions. 
EXPERIMENTAL PROCEDURES 
Materials - Synthetic complete media and 
yeast nitrogen base were obtained from Q-biogene 
(MP Biomedicals).  Myristoyl 
lysophosphatidylethanolamine and oleoyl 
lysophosphatidylserine were from Avanti Polar 
Lipids (Alabaster, AL).  [1-14C] palmitoyl –
lysophosphatidylcholine (lysoPC) (55mCi/mmol) 
was from Perkin-Elmer Life Sciences.  
Nourseothricin was obtained from Werner 
BioAgents.  All other chemicals were obtained 
from either Sigma or Fisher. 
Yeast strains - Molecular biology and yeast 
genetic procedures were performed according to 
conventional protocols (25).  Deletion mutant 
strains for SLC1 and LPT1 were generated by 
homologous recombination in a W303-1B haploid 
(MATa ade2–1, can1–1, trp1–1, ura3–1, his3–11, 
15, leu2–3, 112) (26) by transformation with PCR 
derived products containing 50 bp of gene-specific 
sequence flanking the Kluyveromyces lactis URA3 
sequence (27,28). For LPT1: LPT1F, 5' 
ATGTACAATCCTGTGGACGCTGTTTTAACA
AAGATAATTACCAACTATGGACATGGCAA
TTCCCGGGGATCGL and LPT1R, 5’ 
CTACTCTTCCTTTTTTGAAATAGGCTTTGGT
GAGTAACCACTAAAACTCATCAACATGGT
GGTCAGCTGGAATT.  For SLC1:  SLC1F, 5’ 
ATGAGTGTGATAGGTAGGTTCTTGTATTAC
TTGAGGTCCGTGTTGGTCGTACATGGCAAT
TCCCGGGGATCG and SLC1R, 5’ 
TTAATGCATCTTTTTTACAGATGAACCTTC
GTTATGGGTATTGACATCGTTCAACATGGT
GGTCAGCTGGAATT.  Successful deletion was 
confirmed by PCR using gene specific primers.  
Yeast were grown in YP media (1% yeast extract, 
2% peptone) with 2% glucose (YPD) or in 
synthetic complete (SC) media (29).  
Synthetic lethality screen - SGA was 
performed as described previously (24). A MATα 
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slc1Δ::NatMX4 can1Δ::STE2pr-Sp_his5 lyp1Δ 
strain was crossed to an array containing the set of  
~5, 000 viable deletion mutant strains.   
Yeast Expression Plasmid Construction - A 
PCR product including the LPT1 open reading 
frame, 90 bp of 5' flanking sequence and 46 bp of 
3’ flanking sequence was generated using the 
primers: 175-1, 
CAAAATACAGGCACAGGTCAAGC; 175-2, 
GACAACAAGACTGTGACTTCCAC, and 
W303-1B genomic DNA.  The 2.0-kb PCR 
product was cloned into pCR2.1 TOPO 
(Invitrogen) and subsequently subcloned (NotI / 
SacI) into pRS423GP to create pRS423GP-LPT1. 
Pulse-labeling - Pulse labeling of yeast was 
performed for 30 minutes with log phase cultures 
cultured in YPD with [3H]oleate as described 
previously (30).  Phospholipids were resolved by 
thin layer chromatography in chloroform: 
methanol: acetic acid: water (50:25:8:4) and 
neutral lipids were resolved as previously (30).    
Each lane was cut according to lipid standards and 
counted by liquid scintillation.  Assays were 
performed on a minimum of two independent 
strains of each genotype on two different days.  
Statistical analysis was performed using t tests. 
Preparation of cell lysates, mitochondria and 
microsomes - Yeast cells were grown in YP 
containing either 2% glucose or 3% glycerol at 30° 
C into early stationary phase (O.D.660 = 1.0).  SC-
His media containing 2% galactose was used for 
yeast harboring a plasmid.  The cells were 
harvested, washed and cell lysates prepared as 
described previously (30).  Mitochondria were 
prepared using a previously published protocol 
(31). Briefly, cells were grown in YP media 
containing 3% glycerol, harvested, lysed and crude 
mitochondria were precipitated by centrifugation 
at 12,000 x g.  Resuspension of the pellet, 
followed by sucrose step gradients allowed 
purified mitochondria to be collected.  
Microsomes were purified from the 12,000 x g 
supernatant by precipitation by centrifugation at 
100,000 x g for 1 hour (30).  Lowry assays were 
used to measure protein concentration. 
AGPAT and LPLAT assays, 
spectrophotometric method - 1-acyl-sn-glycerol-3-
phosphate acyltransferase (AGPAT) activity was 
measured by the reaction of thiol groups of the 
released coenzyme A (CoA) with DTNB resulting 
in absorbance at 412nm (32).  The reaction 
mixture contained 100 mM Tris-HCl, pH 7.4, 1.5 
mM DTNB, 50 μM lysophosphatidic acid 
(lysoPA), 50 μM acyl CoA, cell lysate (210 - 840 
μg) in a total volume of 1 ml.  The reaction was 
monitored in real time for 3 minutes in a 
Spectronic Genesys 2 spectrophotometer at room 
temperature.  A molar absorbance of 13,600 M-1 
cm-1 was used to calculate relative specific 
activity.  Lysophospholipid acyltransferase 
(LPLAT) activity was measured by replacing 
lysoPA with lysoPC, lysoPE, lysoPI, or lysoPS 
LPCAT assay, radioactive substrate - 
Lysophosphatidylcholine acyltransferase (LPCAT) 
activity was measured by the incorporation of [1- 
14C] palmitoyl lysoPC into PC.  The reaction 
contained 100 mM Tris-HCl, pH 7.4, 50 μM [1- 
14C] palmitoyl lysoPC (50,000 dpm / nmol), 1 - 
110 μM of the respective acyl-CoA, and 3μg of 
cell lysate protein in a final volume of 100 μl.  
Fixed time assays were performed for 5 minutes at 
28 °C.  The reactions were stopped by adding 
chloroform: methanol (2:1) and lipids were 
extracted and resolved as described elsewhere 
(20).  EZ-Fit software was used for non-linear 
regression, curve fit analysis to calculate Km and 
Vmax.  To calculate Vmax / Km, Vmax was first 
changed to nM / min / mg to remove volume from 
the units of the ratio.  
RESULTS 
SGA screen with slc1Δ identified LPT1 - In 
order to identify the second 1-acyl-sn-glycerol-3-
phosphate acyltransferase (AGPAT) in S. 
cerevisiae, a synthetic genetic array (SGA) screen 
(24) was carried out using an slc1Δ query strain. 
The primary screen identified 52 non-essential 
genes that resulted in a synthetic lethal/sick 
phenotype when disrupted in combination with 
deletion of SLC1 (data not shown).  While the 
primary screen often contains a number of false 
positive interactions, some functionally relevant 
genes were identified including the fatty acid 
elongase gene, ELO2.  The screen also identified 
two genes, PMT5 and YOR175C, which were 
previously shown to exhibit genetic interactions 
with SLC1 (33). PMT5 encodes for a component 
of the dolichyl-phosphate-mannose-protein 
mannosyltransferase complex while a function for 
YOR175c (from here on referred to as LPT15) was 
uncharacterized previously.  To confirm the 
synthetic-lethal interaction, independent slc1Δ and 
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lpt1Δ haploid strains were generated and mated to 
form compound heterozygous diploids.  Following 
meiosis, eighty haploid spores were isolated by 
tetrad dissection.  Sixty spores were viable and all 
were of the wild-type, slc1Δ or lpt1Δ genotype.  In 
line with Hardy Weinberg equilibrium, ¼ of the 
progeny were therefore inviable and slc1Δlpt1Δ, 
confirming the synthetic lethal interaction.  
Lpt1p primary structure - The LPT1 gene 
encodes for a predicted protein of 619 amino acids 
and 72.2 kDa.  Computer algorithm analysis 
predicts seven transmembrane domains (33).  The 
C-terminal four amino acids, KKEE, agree with 
the conserved ER retention signal KKXX (34).  
This is consistent with studies that have shown 
Lpt1p to co-purify with ribosomes (35) and a 
Lpt1p-green fluorescent protein chimera to 
localize to the endoplasmic reticulum (36).  In 
terms of homology, Lpt1p belongs to the 
membrane bound o-acyltransferase (MBOAT) 
family of proteins (37).  Within the MBOAT 
domain (Pfam PFO3062), Lpt1p shares about 25% 
identity with three characterized members of the 
MBOAT family in humans (Fig. 2).  The presence 
of this domain in Lpt1p is consistent with it being 
an acyltransferase.  
Determining if altering LPT1 expression alters 
AGPAT activity - Initial experiments 
characterizing the acyltransferase activity in yeast 
cell lysates were performed by measuring the 
release of coenzyme A from acyl-CoA substrates.  
Assays with and without lysophosphatidic acid 
(lysoPA) were performed in parallel so that 
lysoPA-independent CoA generation could be 
measured and subtracted.  This "background" 
activity was not different between wild-type and 
lpt1Δ samples.  Two acyl-CoA species, palmitoyl-
CoA and oleoyl-CoA, were provided to represent 
saturated and monounsaturated substrates.  To 
establish the amount of Slc1-independent AGPAT 
activity in yeast, slc1Δ cell lysates were assayed 
and showed a 60% reduction, with either acyl-
CoA, compared to wild-type yeast (Fig. 3A).  In 
contrast, lpt1Δ cell lysates showed no statistically 
significant changes in AGPAT activity.  However, 
over-expression of LPT1 resulted in a 7-fold 
increase in AGPAT activity (Fig. 3B).  This 
suggests that Lpt1p can mediate the reaction but in 
the early stationary phase of growth, from which 
these cells were harvested, Slc1 is the primary 
AGPAT. 
Lpt1p esterifies other lysophospholipids - 
Since yeast have been shown to mediate 
lysophosphatidylcholine acyltransferase activity 
(LPCAT) (2,23) we tested if Lpt1p is also 
responsible for that activity.  Similar assays to the 
above were performed by replacing lysoPA with 
lysoPC.  Activity was seen with wild-type yeast 
cell lysates supplied with palmitoyl-CoA, oleoyl-
CoA, and arachidonyl-CoA representing saturated, 
monounsaturated, and polyunsaturated substrates 
(Fig. 4A).  Unsaturated acyl-CoAs showed 4-7 
fold higher activity than the saturated palmitoyl-
CoA.  No activity was observed in lpt1Δ cell 
lysates with any of the acyl-CoAs, suggesting that 
Lpt1p is the main, if not only, LPCAT in yeast.  
Similar assays using [14C]lysoPC and oleoyl-CoA 
showed essentially no activity with lpt1Δ cell 
lysates (0.2 ± 0.2 nmol / min /mg) and robust 
activity in wild-type lysates (55.6 ± 4.7 nmol / min 
/ mg).  To address the possibility that Lpt1p is an 
accessory protein, necessary for the expression 
and/or activity of the true LPCAT, Lpt1p was 
over-expressed in wild-type yeast.  LPCAT 
activity was increased 7-fold compared to wild-
type yeast harboring an empty vector (Fig. 4B), 
consistent with Lpt1p being the catalyst of the 
observed activity.  LysoPC-independent activity 
was modestly increased (11.5 vs. 6.9 
nmol/min/mg) with LPT1 over-expression. 
Since Lpt1p may be the only LPCAT in yeast, 
we hypothesized that it will have broad substrate 
specificity regarding lysophospholipids.  
Replacing lysoPC with lysophosphatidyl-
ethanolamine (lysoPE), lysophosphatidylinositol 
(lysoPI) or lysophosphatidylserine (lysoPS) 
showed distinct acyltransferase activity (Fig. 5A, 
B).  Comparing the enzyme activities of each 
lysophospholipid with oleoyl-CoA suggests that 
Lpt1p has a substrate preference of lysoPC = 
lysoPI = lysoPS > lysoPE (Figs. 4, 5).  Since 
Lpt1p can use multiple lysophospholipids as 
substrates, it should be referred to as a 
lysophospholipid acyltransferase (LPLAT). 
Acyl-CoA substrate specificity for Lpt1p - The 
ability to esterify lysophospholipids suggests that 
Lpt1p is involved in phospholipid remodeling.  
This hypothesis predicts that Lpt1p will 
preferentially utilize unsaturated acyl-CoA 
substrates.  To test this, we performed substrate 
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concentration series experiments with [14C]lysoPC 
and the four acyl-CoA species commonly found in 
yeast: palmitoyl-CoA (16:0), palmitoleoyl-CoA 
(16:1), stearoyl-CoA (18:0), and oleoyl-CoA 
(18:1).  Arachidonyl-CoA (20:4) was also 
included to represent polyunsaturated acyl-CoAs.  
Curve fitting of the Michaelis - Menten plots (Fig. 
6) determined the apparent Km and Vmax (Table I).  
Palmitoyl-CoA and stearoyl-CoA showed 
relatively low Km and low Vmax values while the 
monounsaturated palmitoleoyl-CoA and oleoyl-
CoA showed relatively high Km and high Vmax 
values and arachidonyl-CoA showed intermediate 
values.  Since all the reactions have the same, 
although undetermined, enzyme concentration, 
Vmax / Km should be proportional to the catalytic 
efficiency (kcat / Km).  This value tended to be 
higher for the unsaturated acyl-CoAs than the 
saturated acyl-CoAs.  However, due to the very 
low Km for palmitoyl-CoA, this trend was not 
absolute. 
Subcellular location of LPLAT activity - 
Previous studies have identified acyl-CoA 
dependent LPCAT activity in both yeast 
microsomes (23) and mitochondria (22).  To 
determine the subcellular location of LPLAT 
activity, wild-type yeast organelles were separated 
by differential and density-gradient centrifugation.  
Using lysoPC as a representative lysophospholipid 
in LPLAT assays, microsomes contained 10-fold 
enriched activity compared to whole cell lysates 
while mitochondria showed no enrichment (Table 
II).  Since microsomes comprised a much larger 
fraction of total cell protein, they contained 65% 
of total cellular LPLAT activity.  Mitochondria 
contained 2% of total activity with the remainder 
either lost during extraction or in another cellular 
compartment.  No activity was detected in lpt1Δ 
mitochondria, suggesting that there is not a 
second, mitochondrial specific LPCAT.    
Role of Lpt1p in oleate incorporation into 
glycerolipids - We next addressed the 
physiological importance of Lpt1p mediated 
LPLAT activity.  Wild-type and lpt1Δ strains were 
pulse-labeled for 30 minutes with [3H]oleate.  
Incorporation of the radiolabel into PC in lpt1Δ 
strains was 30% less than in wild-type yeast (Fig. 
7).  Incorporation into PE, PI, and PS and neutral 
lipids was not affected.  Since the product of 
AGPAT activity, PA, is required for the de novo 
synthesis of phospholipids and triglycerides, the 
selective effect on PC synthesis may be due to 
attenuated remodeling.  If this is the case, then of 
the exogenous oleate incorporated into PC in wild-
type yeast, 70% is via de novo synthesis and 30% 
is via remodeling.  Why the phenotype was limited 
to PC is unclear.  It may be that the phospholipase 
A2 component of the remodeling cycle 
preferentially generates lysoPC.  
DISCUSSION  
1-acyl-sn-glycerol-3-phosphate acyltransferase 
(AGPAT) mediates the second step in de novo 
triglyceride and phospholipid synthesis.  This 
pathway seems to be well conserved through 
evolution as evidenced by all of the pathway's 
enzymes in S. cerevisiae identified to date having 
a human homolog (38).  These studies were 
initiated to identify a novel AGPAT in yeast that 
would allow a more complete analysis of 
phospholipid metabolism in this model organism 
and potentially identify novel human homologs.  
Since AGPAT activity is required for the de novo 
synthesis of phospholipids, a major component of 
cellular membranes, if there is only one additional 
AGPAT in yeast besides SLC1, a synthetic 
lethality screen should identify this gene.  
Systematically crossing slc1Δ  haploids with each 
of the approximately 5000 viable single-gene 
deletion haploids identified a total of 52 synthetic-
lethal interactions.  One of the identified genes 
was ELO2 (FEN1) which encodes for an acyl-CoA 
elongase required for ceramide synthesis  (39).   
Interestingly, a gain of function mutation, SLC1-1, 
complements yeast that have deficient 
sphingolipid synthesis.  Viability is conferred by 
the synthesis of atypical PI species that contain 
very long chain acyl groups, presumably with 
similar biophysical properties to sphingolipids 
(40).  Perhaps the non-mutated SLC1 produces a 
small amount of such PI species which are 
required when acyl-CoA elongation is limited.  
LPT1 was also identified in the screen and 
chosen for further characterization due to its 
containing a motif found in a family of membrane 
bound o-acyltransferases (MBOATs) (37).  In S. 
cerevisiae, the family members are the acyl-CoA 
sterol acyltransferases, Are1, Are2 (41), and the 
glycosylphosphatidylinositol anchor remodeling 
protein Gup1 (42) and its paralog, Gup2.  In 
humans, the family includes ACAT1, ACAT2, and 
DGAT1.  Lpt1p does not share sequence similarity 
with Slc1 or any other AGPAT.  It also does not 
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share sequence similarity to the 
lysophosphatidylcholine acyltransferases, 
LPCAT1 (20) and LPCAT2 (21), recently 
identified in mouse lung nor the human 
lysophosphatidylglycerol acyltransferase (43).  
Lpt1p does, however, share about 25% overall 
amino acid sequence identity to three 
uncharacterized human genes' translation products.  
Whether these are functional homologs is under 
current investigation.    
The function of Lpt1p was initially 
investigated by comparing in vitro AGPAT 
activity in wild-type and lpt1Δ cell lysates.  
Coenzyme A release was used to monitor AGPAT 
activity as has been described for measuring 
AGPAT, LPCAT, and DGAT activity in rat liver 
homogenates (32).  In a validation of the assay, 
deletion of SLC1 caused a 60% reduction in 
AGPAT activity  which agreed with a previous 
study that found slc1Δ microsomes incorporate 
50% less [14C]glycerol 3-phosphate into 
phosphatidic acid than wild-type cells (12).  No 
statistically significant decrease in activity resulted 
by deleting LPT1.  However, over-expression of 
LPT1 in a wild-type strain conferred a 7-fold 
increase in AGPAT activity.  This data, along with 
the inviability of scl1Δlpt1Δ, suggests that Lpt1p 
is the second yeast AGPAT.  The largely 
unchanged AGPAT activity in lpt1Δ may be due 
to SLC1 up-regulation. 
Subsequent experiments found that Lpt1p has 
a more pronounced role in esterifying 
lysophospholipids besides lysoPA.  Deletion of 
LPT1 completely abrogated LPCAT activity and 
over-expression of LPT1 in a wild-type yeast 
strain increased this activity 7-fold.  Cell 
fractionation studies detected the majority (65%) 
of whole-cell LPCAT activity in microsomes, 
consistent with Lpt1p residing in the ER (35,36).  
While others detected acyl-CoA dependent 
LPCAT activity in yeast mitochondria (22), we 
recovered little acyl-CoA dependent activity (2%) 
in wild-type mitochondria and none in lpt1Δ 
mitochondria.  Supplying wild-type yeast lysates 
with lysoPE, lysoPI, and lysoPS also showed acyl-
CoA dependent acyltransferase activity.  No 
activity was observed in lpt1Δ lysates even with 
providing saturated and unsaturated acyl-CoA 
species.  The substrate preference for 
lysophospholipids seems to be lysoPC = lysoPI = 
lysoPS > lysoPE.   However, these differences 
may reflect a difference in solubility in the assay 
buffer and / or ability to intercalate into 
membranes during the assay and not a difference 
in enzyme affinity.  The ability to esterify lysoPE 
agrees with the recent finding that yeast can 
transport exogenous lysoPE and esterify it (17).  
The use of lysoPI as an acyl acceptor has been 
rarely described in the literature:  in rat brain (44) 
and pancreas (45) and cow brain (46).  This broad 
use of acyl acceptors by Lpt1p prompted using the 
term lysophospholipid acyltransferase (LPLAT) to 
describe its activity.  While no evidence was found 
for Lpt1p-independent LPLAT activity in yeast,  
other such enzymes may exist that are not 
expressed under the growth conditions used here, 
require assay components that were not supplied, 
or use other substrates such as short or very long 
acyl-CoAs. 
As for the four long chain acyl-CoA species 
commonly found in yeast (47), their utilization 
was studied in depth with substrate concentration 
series experiments.  Since these substrates likely 
undergo kinetically distinct steps, such as 
membrane insertion, prior to interacting with 
Lpt1p, all kinetic parameters are considered to be 
apparent.  With lysoPC as the acyl acceptor, the 
saturated acyl-CoAs showed low Km and low Vmax 
values and the monounsaturated acyl-CoAs 
showed relatively high Km and high Vmax values.  
For oleoyl-CoA, the Km is lower and the Vmax 
higher compared to a previous study of yeast 
LPCAT (Km = 152 μM, Vmax = 11 nmol/min/mg) 
(23).   The values also differed from the rat liver 
LPCAT activity with unsaturated acyl-CoA (Km = 
1 - 10 μM; Vmax = 8 - 13 nmol/min/mg) (48).  
Since Vmax is proportional to the turnover rate of 
the enzyme and Km is proportional to the enzyme's 
affinity for substrate, Vmax / Km yields a single 
value for comparing substrate utilization.  This 
value tended to be higher for unsaturated acyl-
CoA species than saturated species.  The presence, 
and not number, of double bonds seems to be 
critical for substrate utilization since arachidonyl-
CoA has four and was actively used.   
Comparing the kinetic parameters to the 
Michaelis-Menten plots indicates some 
discordance. The reason may be that at high acyl-
CoA concentration, activity is limited by a 
detergent effect.  Perhaps a better way to analyze 
the kinetic data is to compare the activity at 
6
physiological cellular concentrations of each acyl-
CoA.  Since yeast have about 0.1 nmol of each 
acyl-CoA in 109 cells (47) and the average volume 
of a yeast haploid is 70 μm3,  the cellular 
concentration of each acyl-CoA is about 2 μM.  If 
this gross estimate is correct, then Lpt1p likely 
mediates similar activity with saturated and 
unsaturated acyl-CoA inside cells.  If the 
physiological acyl-CoA concentrations are 10 μM 
or higher, then the use of unsaturated acyl-CoAs 
will predominate.  
The physiological function of Lpt1p mediated 
LPLAT activity was also investigated by pulse 
labeling wild-type and lpt1Δ strains with 
[3H]oleate.  There was a selective reduction in 
incorporation into PC by 30%.  It seems unlikely 
that this difference is due to decreased AGPAT 
activity since phosphatidic acid provides a 
precursor for all the phospholipid species, 
synthesized via diacylglycerol or CDP-
diacylglycerol, and triglyceride.  More likely, the 
difference is due to the deficient LPLAT activity 
in lpt1Δ.  The lack of an effect on incorporation 
into PE or PI may reflect a low cellular abundance 
of lyso-species of these phospholipids.  Whether S. 
cerevisiae has a phospholipase A2 with preference 
for PC has not been determined.  However, yeast 
actively use PC as an acyl donor for triglyceride 
synthesis, and thus actively produce lysoPC, via a 
phospholipid diacylglycerol acyltransferase 
reaction mediated by Lro1p (49).  This may be the 
main source of Lpt1p substrates.  In addition to 
constitutive remodeling, Lpt1p may also function 
to limit the abundance of lysophospholipids and 
avoid inappropriate stimulation of adenylate 
cyclase in yeast (50).  LPLAT activity also allows 
exogenous lysophospholipids to be salvaged after 
uptake and directly utilized for cell membranes 
(17).   
In S. cerevisiae, the preferential incorporation 
of unsaturated acyl chains into the sn-2 position of 
phospholipids seems to be achieved by a 
combination of substrate selectivity during de 
novo synthesis, primarily by Slc1p, in the 
Kennedy Pathway and remodeling by Lpt1p in the 
Lands cycle.  This is supported by a deletion of 
both genes being lethal and the preference of both 
reactions for unsaturated acyl-CoA substrates.  
Within the family of membrane bound o-
acyltransferases, LPT1 and its orthologs may 
comprise a novel branch with important roles 
regarding phospholipid composition. 
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FIGURE LEGENDS 
 
Figure 1. Pathways for phospholipid synthesis in yeast.  A. De novo synthesis.  B. Remodeling / 
salvage pathways.  Some substrates and products were omitted due to space constraints.  PA, 
phosphatidic acid; DAG, diacylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine; PE, 
phosphatidylethanolamine; PC, phosphatidylcholine. 
 
Figure 2. Alignment of LPT1 and 3 human members of the MBOAT gene family. 
The four amino acid sequences are aligned over the MBOAT motif (Pfam PFO3062).  Positions where 3 
out of 4 amino acids are conserved are boxed.  In parentheses is the position of the first amino acid. acyl-
CoA cholesterol acyltransferase (ACAT); acyl-CoA diacylglycerol acyltransferase (DGAT). 
  
Figure 3. In vitro 1-acyl-sn-glycerol-3-phosphate acyltransferase (AGPAT) assays. A. Cell lysates 
from wild-type, lpt1Δ and slc1Δ haploids, grown to late logarithmic phase, were assayed for AGPAT 
activity by the spectrophotometric method described in "Experimental Procedures". The assay contained 
50μM 1-oleoyl lysophosphatidic acid, 50μM acyl-CoA, 1.5 mM DTNB, 0.42-0.84 mg cell lysate and 100 
mM Tris-HCl, pH 7.4.  palmitoyl-CoA (black), oleoyl-CoA (grey). The data represent mean ± S.E. n = 3-
5. Asterisk indicates statistically significant difference compared with wild-type strain (p< 0.05). B. 
Similar assays were performed with cell lysates from wild-type cells transformed with pRS423GP or 
pRS423GP-LPT1. 
  
Figure 4. In vitro lysophosphatidylcholine acyltransferase (LCPAT) assays.  A. Cell lysates from wild-
type, lpt1Δ and slc1Δ haploids, grown to late logarithmic phase, were assayed for LPCAT activity by the 
spectrophotometric method described in "Experimental Procedures" and in fig. 2 legend except lysoPA was 
replaced with lysoPC. palmitoyl-CoA (black), oleoyl-CoA (grey) and arachidonyl-CoA (striped). The data 
represent mean ± S.E. n = 3-4. Asterisks indicate statistically significant difference compared with wild-
type strain (p< 0.01).  B. Similar assays were performed with cell lysates from wild-type cells transformed 
with pRS423GP or pRS423GP-LPT1. 
 
Figure 5. Lysophospholipid substrate specificity of Lpt1p. A. Lysophosphatidylethanolamine (lysoPE), 
B. lysophosphatidylinositol (lysoPI), or C. lysophosphatidylserine (lysoPS) were used as acyl acceptors 
and LPLAT activity was determined by the spectrophotometric method using cell lysates prepared from 
wild-type yeast. palmitoyl-CoA (black), oleoyl-CoA (gray).  The data represents mean ± S.E. n = 3. 
Asterisk indicates statistically significant difference (p<0.01) between wild-type and lpt1Δ.  
 
Figure 6. Acyl-CoA substrate specificity of Lpt1p.  Cell lysates from lpt1Δ  yeast transformed with 
pRS423GP / LPT1 were assayed for LPCAT activity by the radioactive substrate method described in 
"Experimental Procedures". The reaction contained 50 μM [1-14C] palmitoyl lysophosphatidylcholine, 1 - 
110 μM of acyl-CoA, 3μg of cell lysate, and 100 mM Tris-HCl, pH 7.4 and incubated for 5 minutes at 
28°C. A. palmitoyl-CoA B. palmitoleoyl-CoA C. stearoyl-CoA D. oleoyl-CoA E. arachidonyl-CoA. The 
data represent mean ± S.E. n = 3 - 5. 
 
Figure 7. Incorporation of [3H]oleate into phospholipids and neutral lipids. Wild-type and lpt1Δ yeast 
were grown in YPD to logarithmic phase and pulse-labeled with [3H]oleate for 30 minutes. A. 
Incorporation into the major phospholipids (PC, black; PE, white; PS/PI, striped) B. neutral lipids 
(diglyceride, dark gray; triglyceride, light gray; ergosterol ester, hatched) was measured as described in 
"Experimental Procedures". The data in counts per minute represent mean ± S.E. n = 4. Asterisk indicates 
statistically significant difference between wild-type and lpt1Δ (p<0.05) 
 
11
TABLES 
 
Table I. Kinetic parameters of Lpt1p.  Kinetic data from fig. 6 were used to calculate apparent Km and 
Vmax.  
 
Acyl-CoA Km
(μM) 
Vmax
(nmol / min / mg)
Vmax / Km
(min-1 mg-1)
palmitoyl-CoA (16:0) 1.8 7.8 43 
palmitoleoyl-CoA (16:1) 21 142 69 
stearoyl-CoA (18:0) 5.9 12 20 
oleoyl-CoA (18:1) 49 125 25 
arachidonyl-CoA (20:4) 11 58 52 
 
 
Table II. Subcellular localization of acyl-CoA dependent LPCAT activity. Wild-type yeast were 
grown in YP with 3% glycerol to O.D.660 = 1. Cell lysates, mitochondria and microsomes were isolated as 
described under "Experimental Procedures". LPCAT activity was measured using the spectrophotometric 
method as described in fig. 4. The data represent mean ± S.E. n = 3. 
 
Subcellular 
fraction 
LPCAT activity 
(nmol / min / mg) 
Fold 
enrichment 
Percent 
recovery 
Cell lysate 10.2 ± 0.5   
Mitochondria 8.1 ± 1.9 0.8 ± 0.1 1.9 ± 0.9 
Microsomes 99.2 ± 2.7 9.7 ± 0.2 65.1 ± 14.5 
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Figure 2 
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ACAT1(418) WNVVVHDWLYYYAYKDFLWFFSKRFKSAAMLAVFAVSAVVHEYALAVCLSFF 
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